Krieckaert C[au] - Search Results

Year	Number of Results
2010	2
2011	4
2012	7
2013	5
2014	5
2015	6
2016	1
2017	3
2018	3
2019	4
2020	3
2022	4

1

[TNF inhibitors: the role of drug levels].

Krieckaert CL, Vogelzang EH, Rispens T, Wolbink G. Krieckaert CL, et al. Ned Tijdschr Geneeskd. 2014;158:A6707. Ned Tijdschr Geneeskd. 2014. PMID: 24754928 Review. Dutch.

2

Immunogenicity of biological therapeutics: from assay to patient.

Krieckaert C, Rispens T, Wolbink G. Krieckaert C, et al. Curr Opin Rheumatol. 2012 May;24(3):306-11. doi: 10.1097/BOR.0b013e3283521c4e. Curr Opin Rheumatol. 2012. PMID: 22388644 Review.

3

Biologicals and bone loss.

Krieckaert CL, Lems WF. Krieckaert CL, et al. Ther Adv Musculoskelet Dis. 2012 Aug;4(4):245-7. doi: 10.1177/1759720X12441275. Ther Adv Musculoskelet Dis. 2012. PMID: 22859923 Free PMC article.

4

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.

Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. Krieckaert CL, et al. Arthritis Res Ther. 2010;12(5):217. doi: 10.1186/ar3147. Epub 2010 Oct 20. Arthritis Res Ther. 2010. PMID: 21029481 Free PMC article. Review.

5

The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.

Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: krieckaert clm. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):306-313. doi: 10.55563/clinexprheumatol/nlr4r8. Epub 2019 Aug 30. Clin Exp Rheumatol. 2020. PMID: 31498069 Free article.

6

The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.

Berkhout LC, l'Ami MJ, Krieckaert CLM, Vogelzang EH, Kos D, Nurmohamed MT, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: krieckaert clm. Rheumatology (Oxford). 2020 Jul 1;59(7):1703-1708. doi: 10.1093/rheumatology/kez513. Rheumatology (Oxford). 2020. PMID: 31691828

7

Are we ready for therapeutic drug monitoring of biologic therapeutics?

Krieckaert CL, Lems WF. Krieckaert CL, et al. Arthritis Res Ther. 2011 Aug 2;13(4):120. doi: 10.1186/ar3395. Arthritis Res Ther. 2011. PMID: 21861867 Free PMC article.

8

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Layegh Z, Ruwaard J, Hebing RCF, L' Ami MJ, van der Weele W, Nurmohamed MT, Krieckaert C, Wolbink G. Layegh Z, et al. Among authors: krieckaert c. Int J Rheum Dis. 2019 May;22(5):869-873. doi: 10.1111/1756-185X.13512. Epub 2019 Feb 14. Int J Rheum Dis. 2019. PMID: 30767391

9

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ. l'Ami MJ, et al. Among authors: krieckaert cl. Ann Rheum Dis. 2020 Jul;79(7):e82. doi: 10.1136/annrheumdis-2019-215609. Epub 2019 May 9. Ann Rheum Dis. 2020. PMID: 31072816 No abstract available.

10

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.

L' Ami MJ, Ruwaard J, Krieckaert C, Nurmohamed MT, van Vollenhoven RF, Rispens T, Wolbink GJ. L' Ami MJ, et al. Among authors: krieckaert c. Scand J Rheumatol. 2019 Jul;48(4):266-270. doi: 10.1080/03009742.2019.1577915. Epub 2019 Apr 23. Scand J Rheumatol. 2019. PMID: 31012365

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results